Trial abstract · §3
DREAMS-1 — results
Primary endpoint, absolute and relative effect where derivable, and harms as reported.
§3Results
§3.1Primary endpoint
Table 3. Primary endpoint as reported.
| Endpoint | Result as reported | Certainty |
|---|---|---|
| Change in glycated haemoglobin from baseline to week 24 as monotherapy in Chinese adults with type 2 diabetes | A reduction of approximately 1.6 percentage points at 6 mg versus 0.1 with placebo | Moderate |
| Reproduced from the published report. Where the report states a confidence interval the Institute reproduces it; where it does not, none is constructed. | ||
§3.2Endpoint hierarchy
§3.3Harms as reported
Table 5. Adverse events for Mazdutide from the safety tables the Institute holds for this compound. Where a row names a different trial as its source, the figure is from that trial and not from this one.
| Event | Active, % | Comparator, % | Source trial |
|---|---|---|---|
| Nausea | 32.0 | 8.0 | Phase 3 obesity (6 mg) |
| Diarrhoea | 22.0 | 9.0 | Phase 3 obesity |
| Vomiting | 16.0 | 2.0 | Phase 3 obesity |
| Increased heart rate | — | — | Reported; attributed to the glucagon arm |
| Discontinuation for adverse events | 5.0 | 2.0 | Phase 3 obesity |
Compound Evidence Institute · CEI-TR-0136/3 · https://compoundevidence.com/trials/dreams-1/results/ · retrieved 30 July 2026